Neurophet

Neurophet Financial Leverage

The Financial Leverage (Equity Multiplier) of Neurophet (380550.KQ) as of Oct 26, 2026 is 1.38. In the previous year, Financial Leverage (Equity Multiplier) was -0.19 — a change of -817.61% (higher).

Financial Leverage

1.38

YoY

-817.61%

Last updated:

Financial Leverage (Equity Multiplier) of Neurophet is 2025 1.38 . Financial Leverage (Equity Multiplier) of Neurophet was 2024 -0.19 . It decreases by -817.61% higher compared to the previous year.

The Neurophet Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
-0.30 KRW
Jan 1, 2023
-0.63 KRW
Jan 1, 2024
-0.19 KRW
Jan 1, 2025
1.38 KRW
The Neurophet Financial Leverage history
YEARFinancial LeverageYoY
1.38-817.61%
-0.19-69.49%
-0.63+107.85%
-0.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc generates revenue through the development and sale of brain imaging analysis software, including 'Neurophet SCALE PET' for positron emission tomography (PET) image quantitative analysis and 'Neurophet AQUA' for neurodegenerative brain disease diagnosis support. The company also offers therapeutic medical devices and medical artificial intelligence (AI) solutions. Its primary customers are healthcare providers and medical institutions seeking advanced diagnostic tools and AI-driven healthcare technologies. The products are sold directly to hospitals, clinics, and research institutions that require specialized brain imaging and diagnostic support. Neurophet Inc targets the health care technology sector, focusing on neurology and medical imaging applications. The company's revenue streams include software licensing, device sales, and AI solution subscriptions. Neurophet Inc's business model centers on providing innovative medical technology solutions for neurological conditions. The firm's key products address specific clinical needs in neurodegenerative disease diagnosis and PET image analysis, with a focus on accuracy and efficiency for medical professionals. The company's offerings are designed to enhance diagnostic capabilities in healthcare settings. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

Financial Leverage (Equity Multiplier) of Neurophet is 1.38 in 2025.

Financial Leverage (Equity Multiplier) of Neurophet changed from -0.19 to 1.38, representing a -817.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Neurophet since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Neurophet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neurophet

All Key Metrics — Neurophet